In recent months, weight loss injections have surged in popularity, with many turning to medications like Wegovy and Mounjaro to aid in their weight management journeys. As the NHS began offering Wegovy in 2023 and plans to provide Mounjaro starting March 2025, demand for these treatments has skyrocketed. However, despite the increased interest, it’s essential to understand the pros, cons, and eligibility requirements before opting for these medications.
A Growing Trend: Celebrities and Weight Loss Jabs
The rise of celebrities using medications such as Ozempic to lose weight has contributed to a dramatic increase in the demand for weight loss jabs. Ozempic, primarily used to manage type 2 diabetes, is gaining attention for its weight loss effects, though it’s important to note that it is not approved for weight loss on its own.
In the UK, Wegovy, a medication containing semaglutide, was introduced to NHS patients for weight management in late 2023. However, despite its approval, the rollout has been slow. Only a small proportion of the 3.4 million eligible patients in England have access to this treatment, primarily due to funding limitations. NHS representatives caution that offering it to everyone who qualifies could severely strain the health service’s resources.
With limited availability, many individuals have sought private healthcare providers to gain access to weight loss jabs. However, experts urge caution, highlighting the potential dangers of using these medications without medical supervision, as some patients have experienced serious complications.
Who is Eligible for NHS Weight Loss Jabs?
Before considering these weight loss injections, it’s crucial to understand the eligibility criteria set by the NHS. Patients must undergo an assessment by their healthcare provider to determine their suitability for treatment.
Wegovy (Semaglutide)
Wegovy, a form of semaglutide, is specifically approved for managing obesity and overweight. It is distinct from Ozempic, which is used for type 2 diabetes and should not be prescribed purely for weight loss. The NHS began offering Wegovy in September 2023 as part of a broader strategy to manage obesity.
To be eligible for Wegovy on the NHS, patients must meet one of the following criteria:
A BMI of 35 or higher, with at least one weight-related health condition (such as hypertension or cardiovascular disease)
A BMI between 30 and 34.9, if referred to specialist weight management services
Importantly, Wegovy is intended for individuals struggling with obesity or weight-related medical issues, not those simply wishing to lose a few pounds. It is administered via a weekly injection, and healthcare providers will offer guidance on how to use it.
Mounjaro (Tirzepatide)
Mounjaro, another weight loss medication, is approved for weight management in adults aged 18 and over who meet specific eligibility criteria. It works by regulating appetite, helping users feel full longer and experience fewer food cravings. Like Wegovy, it is recommended that Mounjaro be used alongside a reduced-calorie diet and increased physical activity.
Eligibility for Mounjaro is as follows:
- A BMI of 30 or higher
- A BMI between 27 and 30, with associated weight-related issues such as prediabetes, hypertension, high cholesterol, or heart disease
Mounjaro is available in a pre-filled injection pen, which should be administered once a week. Initial doses start at 2.5mg, with the potential to increase over time to a maximum of 15mg per week. For women using oral contraceptives, a switch to a barrier method is advised, as Mounjaro may affect the effectiveness of birth control pills.
Should You Consider Private Prescriptions?
Both Wegovy and Mounjaro are available through private prescriptions in the UK. These medications are not available over-the-counter, and individuals must first be assessed by a healthcare provider to determine whether they are suitable candidates. Additionally, ongoing medical support is recommended for anyone undergoing treatment.
However, the National Pharmacy Association (NPA) has issued warnings about the growing trend of purchasing unlicensed weight loss injections online. The NPA cautioned that such purchases carry significant risks, and patients should always consult their GP before considering a private prescription for these treatments. This advisory follows reports from the Medicines and Healthcare products Regulatory Agency (MHRA) that nearly 50 individuals were hospitalized after using weight loss medications last year.
The MHRA emphasizes that medications like Wegovy and Mounjaro are generally safe and effective when used according to their licensed purposes, either for weight management or type 2 diabetes. However, the regulatory agency stresses that these benefits are only guaranteed for patients who meet the appropriate medical criteria.
Related topic：
How Do Fast-Acting Fat Burner Pills Work
How Do Weight Loss Pills Fit into Long-Term Weight Management
